Keros Therapeutics, Inc.
For the period ended Dec 31, 2025. Filed Mar 4, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Mar 4, 2026
KROS$9.17-2.0%Stored close · as of Nov 9, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Balance Sheets
| DECEMBER 31, | ||
|---|---|---|
| 2025 | 2024 | |
| ASSETS | ||
| CURRENT ASSETS: | ||
| Cash and cash equivalents | $287,415 | $559,931 |
| Accounts receivable | 3,567 | 2,742 |
| Prepaid expenses and other current assets | 22,202 | 26,220 |
| Current income tax receivable | 2,250 | — |
| Total current assets | 315,434 | 588,893 |
| Operating lease right-of-use assets | 16,841 | 19,251 |
| Property and equipment, net | 4,297 | 4,237 |
| Restricted cash | 1,449 | 1,449 |
| Other long term assets | — | 2,056 |
| TOTAL ASSETS | $338,021 | $615,886 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||
| CURRENT LIABILITIES: | ||
| Accounts payable | $1,967 | $4,602 |
| Current portion of operating lease liabilities | 2,408 | 1,978 |
| Accrued expenses and other current liabilities | 16,039 | 20,870 |
| Total current liabilities | 20,414 | 27,450 |
| Operating lease liabilities, net of current portion | 14,475 | 16,883 |
| Total liabilities | 34,889 | 44,333 |
| COMMITMENTS AND CONTINGENCIES (Note 14) | ||
| STOCKHOLDERS’ EQUITY: | ||
| Preferred stock, par value of $0.0001 per share; 10,000,000 shares authorized as of December 31, 2025 and 2024; no shares issued and outstanding | — | — |
| Series A junior participating preferred stock, par value of $0.0001 per share; 500,000 and no shares authorized as of December 31, 2025 and December 31, 2024, respectively; no shares issued and outstanding | — | — |
| Common stock, par value of $0.0001 per share; 200,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 40,670,466 shares issued and 19,543,706 shares outstanding as of December 31, 2025 and 40,554,705 shares issued and outstanding as of December 31, 2024 | 4 | 4 |
| Treasury stock, at cost; 21,126,760 and no shares as of December 31, 2025 and December 31, 2024, respectively | (384,558) | — |
| Additional paid-in capital | 1,169,451 | 1,140,328 |
| Accumulated deficit | (481,765) | (568,779) |
| Total stockholders’ equity | 303,132 | 571,553 |
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $338,021 | $615,886 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.